On Tuesday, Arcus Biosciences Inc (NYSE: RCUS) was 8.45% up from the session before settling in for the closing price of $14.56. A 52-week range for RCUS has been $13.49 – $20.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 164.80% over the past five years. When this article was written, the company’s average yearly earnings per share was at 19.56%. With a float of $48.11 million, this company’s outstanding shares have now reached $75.50 million.
Let’s look at the performance matrix of the company that is accounted for 577 employees. In terms of profitability, gross margin is 96.2%, operating margin of -120.91%, and the pretax margin is -102.28%.
Arcus Biosciences Inc (RCUS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arcus Biosciences Inc stocks. The insider ownership of Arcus Biosciences Inc is 47.43%, while institutional ownership is 54.43%. The most recent insider transaction that took place on Aug 13 ’24, was worth 20,314. In this transaction Chief Accounting Officer of this company sold 1,357 shares at a rate of $14.97, taking the stock ownership to the 19,070 shares. Before that another transaction happened on Mar 27 ’24, when Company’s Chief Operating Officer sold 11,551 for $17.55, making the entire transaction worth $202,720. This insider now owns 215,253 shares in total.
Arcus Biosciences Inc (RCUS) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -1.08 earnings per share (EPS) during the time that was less than consensus figure (set at -1) by -0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.56% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.80% during the next five years compared to -23.70% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
You can see what Arcus Biosciences Inc (RCUS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.15, a number that is poised to hit -1.25 in the next quarter and is forecasted to reach -4.33 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Arcus Biosciences Inc (NYSE: RCUS) saw its 5-day average volume 0.74 million, a positive change from its year-to-date volume of 0.73 million. As of the previous 9 days, the stock’s Stochastic %D was 31.86%. Additionally, its Average True Range was 1.06.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 41.58%, which indicates a significant increase from 33.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.59% in the past 14 days, which was higher than the 62.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.30, while its 200-day Moving Average is $16.38. Nevertheless, the first resistance level for the watch stands at $16.81 in the near term. At $17.82, the stock is likely to face the second major resistance level. The third major resistance level sits at $19.05. If the price goes on to break the first support level at $14.57, it is likely to go to the next support level at $13.34. The third support level lies at $12.33 if the price breaches the second support level.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
There are 91,512K outstanding shares of the company, which has a market capitalization of 1.44 billion. As of now, sales total 117,000 K while income totals -307,000 K. Its latest quarter income was 48,000 K while its last quarter net income were -92,000 K.
